Tarsus COO receives 26,287 shares from RSU vesting

Tarsus Pharmaceuticals, Inc. Chief Operating Officer Seshadri Neervannan reported equity compensation activity tied to restricted stock units.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. Chief Operating Officer Seshadri Neervannan reported equity compensation activity tied to restricted stock units. On March 15, 2026, vested RSUs were settled into 26,287 shares of common stock at an exercise price of $0.00 per share.

The RSUs were granted under the Tarsus 2020 Stock Plan across awards from 2022 through 2025, each vesting in four annual 25% installments on March 15, subject to continuous service. After these settlements, Neervannan directly holds 97,104 shares of common stock.

The filing also shows 475 shares of common stock held indirectly by his daughter, with an explicit disclaimer that he does not beneficially own those securities for Section 16 or other purposes.

Insider Trade Summary

26,287 shares exercised/converted

Exercise 6 txns

Insider Neervannan Seshadri

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	5,097	$0.00	$0.00
Exercise	Restricted Stock Units	8,148	$0.00	$0.00
Exercise	Restricted Stock Units	8,020	$0.00	$0.00
Exercise	Restricted Stock Units	5,022	$0.00	$0.00
Exercise	Common Stock	26,287	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 39,255 contracts (Direct); Common Stock — 97,104 shares (Direct); Common Stock — 475 shares (Indirect, By daughter)

Footnotes (7)

1. F1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
2. F2. This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
3. F3. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.
4. F4. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.
5. F5. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
6. F6. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
7. F7. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tarsus (TARS) report for its COO?

Tarsus reported its COO, Seshadri Neervannan, settled vested restricted stock units into 26,287 shares of common stock. These equity awards are part of long-term compensation, granted under the 2020 Stock Plan with multi-year annual vesting tied to continued service.

How many Tarsus (TARS) shares does the COO hold after this Form 4?

After the March 15, 2026 RSU settlements, the COO directly holds 97,104 shares of Tarsus common stock. This reflects accumulated equity compensation from multiple RSU grants that vest in 25% tranches each year over four years under the company’s stock plan.

Were the Tarsus (TARS) COO’s transactions open-market buys or sales?

The reported transactions were not open-market buys or sales; they were exercises of restricted stock units converting into 26,287 common shares at $0.00 per share. This represents routine settlement of vested equity awards, rather than discretionary trading in the public market.

What do the Tarsus (TARS) RSU footnotes say about vesting?

Footnotes state RSUs granted in 2022, 2023, 2024 and 2025 each vest 25% on March 15 over four consecutive years, contingent on continuous service. Each RSU converts into one common share when vested, explaining the COO’s March 15, 2026 share issuance.

How are the Tarsus (TARS) shares held by the COO’s daughter treated?

The filing discloses 475 shares held indirectly by the COO’s daughter, who shares his household. It explicitly states he disclaims beneficial ownership of these securities, and the report should not be considered an admission of beneficial ownership for Section 16 or any other purpose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neervannan Seshadri

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		26,287	A	(1)	97,104	D
Common Stock								475	I	By daughter(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	03/15/2026		M			5,097	(4)	(4)	Common Stock	5,097	$0	0	D
Restricted Stock Units	(3)	03/15/2026		M			8,148	(5)	(5)	Common Stock	8,148	$0	8,148	D
Restricted Stock Units	(3)	03/15/2026		M			8,020	(6)	(6)	Common Stock	8,020	$0	16,040	D
Restricted Stock Units	(3)	03/15/2026		M			5,022	(7)	(7)	Common Stock	5,022	$0	15,067	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

2. This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.

3. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

4. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

5. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

6. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

7. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.